Descriptive table of diagnoses according to severity of COVID-19*
| Classification, n (%) | Overall (n=694) | Patients with mild infection (n=438) | Patients with moderate infection (n=169) | Patients with severe infection (n=87) | Survivors (n=617) | Non-survivors (n=58) |
| Chronic inflammatory arthritis | ||||||
| Rheumatoid arthritis | 213 (30.7) | 129 (29.5) | 55 (32.5) | 29 (33.3) | 187 (30.3) | 20 (34.5) |
| Axial and peripheral spondyloarthritis | 165 (23.8) | 135 (30.8) | 25 (14.8) | 5 (5.8) | 161 (26.1) | 1 (1.7) |
| Psoriatic arthritis | 70 (10.1) | 52 (11.9) | 12 (7.1) | 6 (6.9) | 64 (10.4) | 3 (5.2) |
| Non-systemic idiopathic juvenile arthritis | 2 (0.3) | 2 (0.5) | 0 | 0 | 2 (0.3) | 0 |
| Other inflammatory arthritis | 14 (2.0) | 7 (1.6) | 5 (3.0) | 2 (2.3) | 13 (2.1) | 1 (1.7) |
| Autoinflammatory diseases | ||||||
| Still’s disease | 5 (0.7) | 1 (0.2) | 2 (1.2) | 2 (2.3) | 4 (0.7) | 1 (1.7) |
| Periodic fever syndromes† | 15 (2.2) | 8 (1.8) | 5 (3.0) | 2 (2.3) | 13 (2.1) | 2 (3.5) |
| Systemic idiopathic juvenile arthritis | 3 (0.4) | 2 (0.5) | 1 (0.6) | 0 | 3 (0.5) | 0 |
| Other autoinflammatory diseases | 4 (0.6) | 2 (0.5) | 1 (0.6) | 1 (1.2) | 3 (0.5) | 1 (1.7) |
| Vasculitis | ||||||
| Giant cell arteritis and polymyalgia rheumatica | 30 (4.3) | 8 (1.8) | 10 (5.9) | 12 (13.8) | 21 (3.40) | 9 (15.5) |
| Behcet’s disease | 7 (1.0) | 3 (0.7) | 3 (1.8) | 1 (1.2) | 6 (1.0) | 1 (1.7) |
| Vasculitis associated with cytoplasmic antineutrophil antibodies | 17 (2.5) | 4 (0.9) | 4 (2.4) | 9 (10.4) | 10 (1.6) | 7 (12.1) |
| Takayasu’s arteritis | 1 (0.1) | 1 (0.2) | 0 | 0 | 1 (0.2) | 0 |
| Other vasculitis (including Kawasaki’s disease) | 10 (1.4) | 5 (1.1) | 5 (3.0) | 0 | 9 (1.5) | 0 |
| Systemic autoimmune diseases | ||||||
| Systemic lupus erythematosus | 46 (6.6) | 32 (7.3) | 11 (6.5) | 3 (3.5) | 42 (6.8) | 2 (3.5) |
| Systemic sclerosis | 25 (3.6) | 17 (3.9) | 6 (3.6) | 2 (2.3) | 23 (3.7) | 2 (3.5) |
| Primary Sjögren syndrome | 17 (2.5) | 7 (1.6) | 7 (4.1) | 3 (3.5) | 15 (2.4) | 2 (3.5) |
| Inflammatory myopathy (including dermatomyositis, polymyositis) | 12 (1.7) | 6 (1.4) | 3 (1.8) | 3 (3.5) | 8 (1.3) | 3 (5.2) |
| Undifferentiated connective tissue disease | 3 (0.4) | 3 (0.7) | 0 | 0 | 1 (0.2) | 0 |
| Mixed connective tissue disease | 4 (0.6) | 0 | 3 (1.8) | 1 (1.2) | 3 (0.5) | 1 (1.7) |
| Other | ||||||
| Sarcoidosis | 15 (2.2) | 6 (1.4) | 5 (3.0) | 4 (4.6) | 12 (1.9) | 2 (3.5) |
| Eye inflammation (including uveitis) | 3 (0.4) | 2 (0.5) | 1 (0.6) | 0 | 3 (0.5) | 0 |
| IgG4-related disease | 3 (0.4) | 1 (0.2) | 1 (0.6) | 1 (1.2) | 3 (0.5) | 0 |
| Other | 10 (1.4) | 5 (1.1) | 4 (2.4) | 1 (1.2) | 10 (1.6) | 0 |
*Total number of survivors and non-survivors as presented excludes 19 patients whose status at day 21 was unknown at the time of data cut-off.
†Includes TNF receptor-associated periodic syndrome, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and mevalonate kinase deficiency.
TNF, tumour necrosis factor.